Searchable abstracts of presentations at key conferences in endocrinology

ea0056p138 | Endocrine tumours and neoplasia | ECE2018

Evaluation of neurofibromatosis type 1 and gastroenteropancreatic neuroendocrine tumors.

Percovich Juan Carlos , Atencia Jose , Garcia Rogelio , Sambo Marcel , Blanco Montserrat , Rotger Amanda , Lopez Dolores , Olmedilla Yoko , Picallo Maria , Velez Marian , Agreda Javier , Brox Noemi , Monereo Susana

Introduction: Neurofibromatosis type 1 (NF1) is an autosomal dominant condition with an incidence of 1 in 2600 to 3000 individuals. Patients with this disorder are characterized by multiple neurofibromas, caf-au-lait macules, axillary freckling, optic gliomas, iris hamartomas, and skeletal abnormalities. Overall risk of developing neoplasms is approximately 2 to 4-fold higher in patients with NF1, with a risk of malignancy estimated between 5 and 15%. Endocrinopathies are some...

ea0098t6 | Trials In Progress | NANETS2023

Genetic profiling in the randomized controlled phase 3 COMPOSE trial of 177Lu-edotreotide for well-differentiated aggressive grade 2/3 gastroenteropancreatic neuroendocrine tumors

Halfdanarson Thorvardur R. , Capdevila Jaume , Halperin Daniel M. , Herrmann Ken , Kong Grace , Mailman Josh , Reidy-Lagunes Diane , Srirajaskanthan Raj , Sierras Cristina , Rotger Amanda

Background: Targeted radionuclide therapies (TRTs) have changed the treatment paradigm of neuroendocrine tumors (NET) and are expected to be widely available for patients with various gastroenteropancreatic (GEP)-NET phenotypes. However, while they have great potential, TRT-based therapeutic strategies for high-grade GEP-NET demonstrate variable outcomes, and there is a current lack of tools to identify patients who are likely to respond to TRT. To address this need, the rando...